Stable triple helices formed by oligonucleotide N3'-->P5' phosphoramidates inhibit transcription elongation.

Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Stable triple helices formed by oligonucleotide N3'-->P5' phosphoramidates inhibit transcription elongation.

Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4365-9. Unique Identifier : AIDSLINE MED/96210649
Escude C; Giovannangeli C; Sun JS; Lloyd DH; Chen JK; Gryaznov SM; Garestier T; Helene C; Laboratoire de Biophysique, Museum National d'Histoire; Naturelle, Institut National de la Sante et de la Recherche; Medicale, Paris, France.

Abstract: Oligonucleotide analogs with N3'-->P5' phosphoramidate linkages bind to the major groove of double-helical DNA at specific oligopurine.oligopyrimidine sequences. These triple-helical complexes are much more stable than those formed by oligonucleotides with natural phosphodiester linkages. Oligonucleotide phosphoramidates containing thymine and cytosine or thymine, cytosine, and guanine bind strongly to the polypurine tract of human immunodeficiency virus proviral DNA under physiological conditions. Site-specific cleavage by the Dra I restriction enzyme at the 5' end of the polypurine sequence was inhibited by triplex formation. A eukaryotic transcription assay was used to investigate the effect of oligophosphoramidate binding to the polypurine tract sequence on transcription of the type 1 human immunodeficiency virus nef gene under the control of a cytomegalovirus promoter. An efficient arrest of RNA polymerase II was observed at the specific triplex site at submicromolar concentrations.

Keywords: Amides Antiviral Agents/CHEMISTRY/*PHARMACOLOGY Base Sequence Cell Nucleus/METABOLISM Cytomegalovirus/GENETICS DNA/CHEMISTRY Genes, nef Hela Cells Human HIV-1/*DRUG EFFECTS/GENETICS/METABOLISM Kinetics Molecular Sequence Data Nucleic Acid Conformation Nucleic Acid Denaturation Oligodeoxyribonucleotides/CHEMISTRY/*PHARMACOLOGY Phosphoric Acids Promoter Regions (Genetics) Support, Non-U.S. Gov't Thermodynamics Transcription, Genetic/*DRUG EFFECTS JOURNAL ARTICLE
960930
M9690888

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .